Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Jefferies Healthcare Conference
Presentation date: Wednesday, June 8, 2022
Presentation time: 2:30 PM ET
Location: Marriott Marquis, New York, NY
Goldman Sachs 43rd Annual Global Healthcare Conference
Dates: June 13-16, 2022
1x1 meetings only
Location: Terranea Resort, Ranch Palos Verdes, CA
JMP Securities Life Sciences Conference
Fireside Chat date: Thursday, June 16, 2022
Presentation time: 11:00 AM ET
Location: The Lotte New York Palace Hotel, New York, NY
Stifel’s 2022 Virtual Cell Therapy Summit
Dates: June 29-30, 2022
Live webcasts and archived replays of key presentations will be available on the Company's website at https://ir.vorbio.com/news-and-events/events-and-presentations.
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Investors & Media
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.60 |
| Daily Change: | -0.14 -8.05 |
| Daily Volume: | 6,102,541 |
| Market Cap: | US$202.690M |
August 27, 2025 July 21, 2025 June 25, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
